Lupirtin-SR — Flupirtine Maleate 400 mg

Lupirtin-SR is supplied as uncoated, sustained-release matrix tablets. Each tablet contains:

• Active Ingredient: Flupirtine Maleate — 400 mg.
• Inactive Core Excipients: Hypromellose (HPMC, matrix-forming polymer), lactose monohydrate, microcrystalline cellulose, magnesium stearate, colloidal anhydrous silica, and Iron Oxide Yellow as a colorant.

Pharmacodynamics: Flupirtine is a Selective Neuronal Potassium Channel Opener (SNEPCO) targeting Kv7/KCNQ potassium channels. Stabilizing the resting membrane potential of nerve cells through potassium efflux blocks the propagation of ascending nociceptive impulses. Furthermore, flupirtine works as a functional NMDA receptor antagonist, preventing downstream calcium influx associated with chronic neuronal excitability. This combined activity yields analgesia, muscle relaxation, and helps mitigate central pain sensitization.

Pharmacokinetics: The sustained-release profile ensures gradual oral absorption. Systemic bioavailability ranges between 60% and 70%. Hepatic processing produces an active N-acetylated metabolite (M1) which contributes to the analgesic profile. The terminal half-life (T1/2) for this sustained-release formulation is significantly extended to roughly 15–22 hours, allowing for once-daily therapeutic coverage. Elimination occurs primarily via renal clearance (approx. 70%) and secondarily through feces.

Lupirtin-SR 400 mg is indicated for adult patients for the management of the following pain presentations:

• 🔹 Musculoskeletal and Myofascial Pain: Acute or chronic back pain, lumbar spasms, dorsalgia, and spondylogenic muscular tension.
• 🔹 Post-Orthopedic & Surgical Recovery: Relief of moderate pain following orthopedic surgery, structural trauma, or dental extractions when conventional alternatives are contraindicated.
• 🔹 Neuralgias: Management of nerve-related pain, including sciatica and radiculopathy.

Lupirtin-SR administration must be supervised closely by a healthcare professional with routine diagnostic follow-ups:

• Standard Regimen: The typical adult dosage is 1 tablet (400 mg) taken orally once daily. The exact therapeutic course should be individualized depending on pain severity.
• Administration Rules: Tablets must be swallowed whole with a full glass of water, independent of meals. Do not chew, crush, split, or dissolve the tablet, as this destroys the sustained-release matrix and causes immediate dumping of the drug.
• Duration and Safety: Due to potential risks of hepatotoxicity, the treatment duration should be kept as short as clinically feasible (typically not exceeding 1–2 weeks), accompanied by mandatory weekly Liver Function Tests (LFTs).

Lupirtin-SR is contraindicated under the following physiological and medical profiles:

• ⛔ Hepatic Dysfunction: Pre-existing liver disease, active hepatitis, cholestasis, or severe hepatic impairment.
• ⛔ Hypersensitivity: Documented allergic response to flupirtine maleate or any underlying binder.
• ⛔ Concomitant Substance Use: History of alcohol abuse or concurrent use of other known hepatotoxic medications.
• ⛔ Pregnancy, Lactation, and Pediatric Use: Completely contraindicated during pregnancy, in nursing mothers, and in pediatric patients under 18 years of age.

Co-administration of Lupirtin-SR requires careful consideration of the following drug interaction profiles:

• ⚠️ CNS Depressants & Alcohol: Flupirtine enhances the effects of alcohol, sedatives, hypnotics, tranquilizers, and other muscle relaxants.
• ⚠️ Anticoagulants: Highly protein-bound, flupirtine can displace warfarin or coumarin derivatives, necessitating close monitoring of prothrombin time and INR parameters.
• ⚠️ Hepatotoxic Agents: Avoid concurrent use with paracetamol (acetaminophen), carbamazepine, or other medications that induce heavy hepatic metabolic load.

Reproductive protection protocols during Lupirtin-SR therapy:

• Contraception: Women of childbearing potential must deploy highly reliable barrier or hormonal contraceptive methods throughout the duration of the prescription.
• Pregnancy and Lactation: Contraindicated. Adequate, well-controlled clinical safety studies on pregnant or lactating individuals are absent. If therapy becomes mandatory during lactation, breastfeeding must be terminated.

Potential adverse reactions that may surface during Lupirtin-SR management include:

• 🟢 General Constitutional (Common): Fatigue, mild dizziness, dry mouth, transient nausea, and heartburn.
• 🟡 Central Nervous System: Drowsiness, minor extremity tremors, headache, or sleep disturbances (uncommon).
• 🔴 Hepatic Safety (Critical): Asymptomatic elevations in serum transaminases (ALT, AST). Rare occurrences of drug-induced hepatitis or clinical jaundice have been documented. Discontinue use immediately if unexpected fatigue, dark urine, or scleral icterus appears.

Clinical management guidelines in the event of an acute overdose of Lupirtin-SR:

• Symptoms: Clinical toxicity manifests as severe somnolence, confusion, nausea, severe dry mouth, tachycardia, and disorientation.
• Management: No specific antidote exists. Treatment centers on primary decontamination (gastric lavage if caught early), administration of activated charcoal to limit gut absorption, forced diuresis, and comprehensive supportive intensive care.

Storage environments required to protect the sustained-release structural properties:

• 🌡️ Environmental Range: Store within the original protective packaging in a cool, dry location shielded from direct light at a room temperature not exceeding 25–30 °C. Maintain protection against moisture.
• 👶 Child Safety: Keep the blister packs securely stored far out of the line of sight and reach of children.
• ⏳ Shelf Life: 2 years. Do not consume any tablets that have crossed the expiration date (EXP) stamped on the packaging.

Genuine Lupirtin-SR by Lupin Ltd. implements robust export-grade pharmaceutical packaging safeguards to help patients identify authentic medications:

• 🛡️ Official Lupin Branding: The exterior carton and the metallic foil of the blister pack feature Lupin's registered trademark green logo (a stylized tree symbol bounded by a border). Print registration must be pristine, without blurriness, overlapping ink, or bleeding. The product name Lupirtin-SR is consistently rendered in distinct blue type accompanied by a registered trademark icon (®).
• 🔒 Red-Bordered Schedule H Warning: The side panel of the retail carton and the foil backing of each blister strip include a bright red text box declaring: "SCHEDULE H PRESCRIPTION DRUG - CAUTION: Not to be sold by retail without the prescription of a Registered Medical Practitioner." This is a mandated legal requirement for Indian prescription narcotics and analgesics.
• 🔍 Alu-Alu Matrix Strip Profiles: Tablets are distributed in robust 10-tablet strip configurations. The backing features a silver foil finish printed with the exact product title, Lupin's Mumbai corporate credentials, and the factory manufacturing license number (Mfg. Lic. No.). The physical tablets inside possess a distinctive uniform pale-yellow color resulting from the inclusion of iron oxide.
• 🔢 Coordinated Batch & Date Stamp (Batch/MFG/EXP): The closing end-flap of the carton box and the side margin of every individual blister strip feature matching embossed alphanumeric details outlining the unique Batch Number (BATCH NO.), Manufacturing Date (MFG. DATE), and Expiration Date (EXPIRY). These numbers must correlate completely across all packaging elements without alterations.